From plasma membrane to cytoskeleton: a novel function for semaphorin 6A.

@article{Prislei2008FromPM,
  title={From plasma membrane to cytoskeleton: a novel function for semaphorin 6A.},
  author={Silvia Prislei and Simona Mozzetti and Flavia Filippetti and Marta De Donato and Giuseppina Raspaglio and Lucia Cicchillitti and Giovanni Scambia and Cristiano Ferlini},
  journal={Molecular cancer therapeutics},
  year={2008},
  volume={7 1},
  pages={233-41}
}
Class III beta-tubulin (TUBB3) overexpression has been reported in ovary, lung, breast, and gastric cancer patients. Currently, no clinical drugs are available for a specific targeting of TUBB3, whereas the investigational drug IDN5390 specifically interacts with TUBB3. To gain insight into the pathways leading to TUBB3 up-regulation, we did a human genome… CONTINUE READING